Ovarian Tissue Cryopreservation to Help Ensure Future Fertility
Women with cancer who need to begin chemotherapy regimens as quickly as possible but would like to be able to conceive at a later date may have a new option.
The procedure is called Ovarian Tissue Cryopreservation. In it, doctors remove a section of ovarian tissue from one ovary that contains eggs, then freeze the tissue prior to the start of chemotherapy. Available to women between the ages of 18 and 42, the patient will have access to 80% of the removed tissue for the future; the other 20%, it appears, will be donated over to research.
About 25 sites across the US are offering the procedure, in collaboration with The Oncofertility Consortium at Northwestern University.
Benefits: The procedure takes no more than one or two days and doesn't involve hormones—two significant features that even make the procedure possible for female patients as young as one year old.
Source: Medical News Today
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
